

# Author Index Volume 10 (2011/2012)

The issue number is given in front of the pagination

- Abu-Soud, H.M., see Fletcher, N.M. (6) 267–275  
Ackermann, H., see Tsaur, I. (5) 195–204  
Adebisi, I.N., see Pereira, L.H.M. (5) 241–249  
Aglietti, M.C., see Mearini, L. (3,4) 117–123  
Ali-Fehmi, R., see Fletcher, N.M. (6) 267–275  
Altekruse, S.F., see Man-Sun Sy, M.-S. (6) 251–258  
Andjelkovic, T., J. Bankovic, Z. Milosevic, J. Stojisic, V. Milinkovic, M. Pesic, S. Ruzdijic and N. Tanic, Concurrent alteration of *p16* and *PTEN* tumor suppressor genes could be considered as potential molecular marker for specific subgroups of NSCLC patients (6) 277–286  
Antonacopoulou, A.G., A.E. Kottorou, F.-I.D. Dimitrakopoulos, V. Triantafyllia, S. Marousi, A. Koutras and H.P. Kalofonos, *VEGF* polymorphisms may be associated with susceptibility to colorectal cancer: A case-control study (5) 213–217  
Bankovic, J., see Andjelkovic, T. (6) 277–286  
Banna, G.L., see Paratore, S. (2) 79–89  
Bartling, B., V. Vanhooren, S. Dewaele, C. Libert, H.-S. Hofmann, J. Haerting, S. Nuding, R.-E. Silber, A. Simm and C.C. Chen, Altered desialylated plasma N-glycan profile in patients with non-small cell lung carcinoma (3,4) 145–154  
Bartsch, G., see Tsaur, I. (5) 195–204  
Bella, V., see Sebova, K. (1) 13–26  
Bellia, D., see Paratore, S. (2) 79–89  
Belotte, J., see Fletcher, N.M. (6) 267–275  
Bigbee, W.L., see Nolen, B.M. (1) 3–12  
Bini, V., see Mearini, L. (3,4) 117–123  
Blaheta, R.A., see Tsaur, I. (5) 195–204  
Blumenschein, Jr., G.R., M. Reck, F. Fossella, D.J. Stewart, C. Lathia and C. Peña, Plasma biomarkers correlating with clinical outcome in a phase II study of sorafenib in advanced NSCLC (6) 287–298  
Bravo-Calderón, D.M., D.T. Oliveira, A.N. Marana, S. Nonogaki, A.L. Carvalho and L.P. Kowalski, Prognostic significance of beta-2 adrenergic receptor in oral squamous cell carcinoma (1) 51–59  
Buscarino, C., see Paratore, S. (2) 79–89  
Cai, Z., see Xu, J. (2) 63–69  
Carter, B., see Ramakrishnan, V. (3,4) 185–193  
Carvalho, A.L., see Bravo-Calderón, D.M. (1) 51–59  
Catlow, J., see McCall, P. (2) 91–99  
Cavallaro, S., see Paratore, S. (2) 79–89  
Cha, E.-J., see Jeong, P. (5) 205–211  
Chen, B., see Niu, H.T. (2) 109–116  
Chen, C.C., see Bartling, B. (3,4) 145–154  
Chen, C.C., see Ramakrishnan, V. (3,4) 185–193  
Chen, J., see Xu, J. (2) 63–69  
Chen, J., see Zheng, Y. (2) 71–77  
Chen, K., see Ma, S. (3,4) 155–162  
Cho, I.-C., see Jeong, P. (5) 205–211  
Choi, S., see Nolen, B.M. (1) 3–12  
Chung, K., N. Nishiyama, S. Yamano, H. Komatsu, S. Hanada, M. Wei, H. Wanibuchi, S. Suehiro and A. Kakehashi, Serum AGR2 as an early diagnostic and postoperative prognostic biomarker of human lung adenocarcinoma (2) 101–107  
Corbett, S., see Topilow, A.A. (1) 27–33  
Cui, L., see Zheng, Y. (2) 71–77  
Cunsolo, R., see Paratore, S. (2) 79–89  
Dacic, S., see Nolen, B.M. (1) 3–12  
D'Arrigo, M., see Paratore, S. (2) 79–89  
Davis, J.M., see Topilow, A.A. (1) 27–33  
de las Rivas, J., see Folio, C. (1) 35–41  
Dewaele, S., see Bartling, B. (3,4) 145–154  
Dey, S., see Gill, K. (3,4) 125–134  
Diamond, M.P., see Fletcher, N.M. (6) 267–275  
Dimitrakopoulos, F.-I.D., see Antonacopoulou, A.G. (5) 213–217  
Dong, Q., see Niu, H.T. (2) 109–116

- Duncan, R., see Pereira, L.H.M. (5) 241–249
- Edwards, J., see McCall, P. (2) 91–99
- Elgaaied, A.B.A., see Ouerhani, S. (6) 259–266
- Endo, S., see Misawa, K. (3,4) 135–144
- Fletcher, N.M., Z. Jiang, R. Ali-Fehmi, N.K. Levin, J. Belotte, M.A. Tainsky, M.P. Diamond, H.M. Abu-Soud and G.M. Saed, Myeloperoxidase and free iron levels: Potential biomarkers for early detection and prognosis of ovarian cancer (6) 267–275
- Folio, C., M. Zalacain, C. Zanduetta, C. Ormazábal, L. Sierrasesúмага, M.S. Julián, J. de las Rivas, G. Toledo, F. Lecanda and A. Patiño-García, Cortactin (CTTN) overexpression in osteosarcoma correlates with advanced stage and reduced survival (1) 35–41
- Fossella, F., see Blumenschein, Jr., G.R. (6) 287–298
- Franzmann, E.J., see Pereira, L.H.M. (5) 241–249
- Fridrichova, I., see Sebova, K. (1) 13–26
- Galbavy, S., see Sebova, K. (1) 13–26
- Gasser, M., see Tsaur, I. (5) 195–204
- Gill, K., B.K. Mohanti, A.K. Singh, B. Mishra and S. Dey, The over expression of cathelicidin peptide LL37 in head and neck squamous cell carcinoma: The peptide marker for the prognosis of cancer (3,4) 125–134
- Gilvarg, C., see Topilow, A.A. (1) 27–33
- Gong, G.-H., see Ha, S.-A. (5) 219–231
- Goodman, M.T., see Man-Sun Sy, M.-S. (6) 251–258
- Goodwin, W.J., see Pereira, L.H.M. (5) 241–249
- Guo, H., see Xu, Q. (5) 233–239
- Guo, J., see Zheng, Y. (2) 71–77
- Ha, S.-A., Y.S. Lee, H.K. Kim, J. Yoo, S. Kim, G.-H. Gong, Y.K. Lee and J.W. Kim, The prognostic potential of keratin 18 in breast cancer associated with tumor dedifferentiation, and the loss of estrogen and progesterone receptors (5) 219–231
- Ha, Y.S., see Jeong, P. (5) 205–211
- Haerting, J., see Bartling, B. (3,4) 145–154
- Haferkamp, A., see Tsaur, I. (5) 195–204
- Hakamada, K., see Misawa, K. (3,4) 135–144
- Hanada, S., see Chung, K. (2) 101–107
- He, J., see Xu, J. (2) 63–69
- Hernandez, B.Y., see Man-Sun Sy, M.-S. (6) 251–258
- Hewitt, S.M., see Man-Sun Sy, M.-S. (6) 251–258
- Hofmann, H.-S., see Bartling, B. (3,4) 145–154
- Honda, K., see Yokomizo, A. (3,4) 175–183
- Hu, J.J., see Pereira, L.H.M. (5) 241–249
- Huesch, T., see Tsaur, I. (5) 195–204
- Huo, M., see Zheng, Y. (2) 71–77
- Iemmolo, R., see Paratore, S. (2) 79–89
- Imai, A., see Misawa, K. (3,4) 135–144
- Jeong, P., Y.S. Ha, J.S. Kim, I.-C. Cho, W.T. Kim, Y.-J. Kim, I.Y. Kim, S.-J. Yun, S.-C. Lee, E.-J. Cha and W.-J. Kim, Runt-related transcription factor 3 methylation as a possible prognosticator in muscle-invasive bladder cancer (5) 205–211
- Jiang, Z., see Fletcher, N.M. (6) 267–275
- Julián, M.S., see Folio, C. (1) 35–41
- Kajabova, V., see Sebova, K. (1) 13–26
- Kajo, K., see Sebova, K. (1) 13–26
- Kakehashi, A., see Chung, K. (2) 101–107
- Kalofonos, H.P., see Antonacopoulou, A.G. (5) 213–217
- Kanai, T., see Yokomizo, A. (3,4) 175–183
- Kanazawa, T., see Misawa, K. (3,4) 135–144
- Kim, H.K., see Ha, S.-A. (5) 219–231
- Kim, I.Y., see Jeong, P. (5) 205–211
- Kim, J.S., see Jeong, P. (5) 205–211
- Kim, J.W., see Ha, S.-A. (5) 219–231
- Kim, S., see Ha, S.-A. (5) 219–231
- Kim, W.-J., see Jeong, P. (5) 205–211
- Kim, W.T., see Jeong, P. (5) 205–211
- Kim, Y.-J., see Jeong, P. (5) 205–211
- Koay, D.C., see Ramakrishnan, V. (3,4) 185–193
- Komatsu, H., see Chung, K. (2) 101–107
- Kottorou, A.E., see Antonacopoulou, A.G. (5) 213–217
- Koutras, A., see Antonacopoulou, A.G. (5) 213–217
- Kowalski, L.P., see Bravo-Calderón, D.M. (1) 51–59
- Krivulcik, T., see Sebova, K. (1) 13–26
- Kumar, C.A., see Sawhney, H. (1) 43–49
- Kurosch, M., see Tsaur, I. (5) 195–204
- Kushwaha, D., see Ramakrishnan, V. (3,4) 185–193
- Langmead, C.J., see Nolen, B.M. (1) 3–12
- Lasabova, Z., see Sebova, K. (1) 13–26
- Lathia, C., see Blumenschein, Jr., G.R. (6) 287–298
- Lazariotou, M., see Tsaur, I. (5) 195–204
- Lecanda, F., see Folio, C. (1) 35–41
- Lee, S.-C., see Jeong, P. (5) 205–211
- Lee, Y.K., see Ha, S.-A. (5) 219–231
- Lee, Y.S., see Ha, S.-A. (5) 219–231
- Levin, N.K., see Fletcher, N.M. (6) 267–275
- Li, C., see Man-Sun Sy, M.-S. (6) 251–258
- Li, J., see Xu, Q. (5) 233–239

- Liang, Z., see Xu, J. (2) 63–69
- Libert, C., see Bartling, B. (3,4) 145–154
- Lipari, H., see Paratore, S. (2) 79–89
- Lokeshwar, V.B., see Pereira, L.H.M. (5) 241–249
- Lokshin, A.E., see Nolen, B.M. (1) 3–12
- Lomakin, A., see Nolen, B.M. (1) 3–12
- Lou, Y., see Zheng, Y. (2) 71–77
- Lucenti, L., see Paratore, S. (2) 79–89
- Luo, X., see Xu, J. (2) 63–69
- Lynch, C.F., see Man-Sun Sy, M.-S. (6) 251–258
- Ma, S., L. Shen, N. Qian and K. Chen, The prognostic values of CA125, CA19.9, NSE, AND SCC for stage I NSCLC are limited (3,4) 155–162
- Makarevic, J., see Tsaur, I. (5) 195–204
- Man-Sun Sy, M.-S., S.F. Altekruze, C. Li, C.F. Lynch, M.T. Goodman, B.Y. Hernandez, L. Zhou, M.S. Saber, S.M. Hewitt and W. Xin, Association of prion protein expression with pancreatic adenocarcinoma survival in the SEER residual tissue repository (6) 251–258
- Mao, Y., see Ramakrishnan, V. (3,4) 185–193
- Marana, A.N., see Bravo-Calderón, D.M. (1) 51–59
- Marousi, S., see Antonacopoulou, A.G. (5) 213–217
- Marrangoni, A., see Nolen, B.M. (1) 3–12
- Matsubara, J., see Yokomizo, A. (3,4) 175–183
- McArdle, P.A., see McCall, P. (2) 91–99
- McCall, P., J. Catlow, P.A. McArdle, D.C. McMillan and J. Edwards, Tumoral C-reactive protein and nuclear factor kappa-B expression are associated with clinical outcome in patients with prostate cancer (2) 91–99
- McMillan, D.C., see McCall, P. (2) 91–99
- Mearini, L., A. Zucchi, E. Scarponi, E. Nunzi, M.C. Aglietti, V. Bini and M. Porena, Correlation between age and Chromogranin A determination in prostate diseases (3,4) 117–123
- Milinkovic, V., see Andjelkovic, T. (6) 277–286
- Milosevic, Z., see Andjelkovic, T. (6) 277–286
- Mineta, H., see Misawa, K. (3,4) 135–144
- Misawa, K., T. Kanazawa, Y. Misawa, A. Imai, S. Endo, K. Hakamada and H. Mineta, Hypermethylation of collagen  $\alpha 2$  (I) gene (COL1A2) is an independent predictor of survival in head and neck cancer (3,4) 135–144
- Misawa, Y., see Misawa, K. (3,4) 135–144
- Mishra, B., see Gill, K. (3,4) 125–134
- Mohanti, B.K., see Gill, K. (3,4) 125–134
- Naito, S., see Yokomizo, A. (3,4) 175–183
- Ng, K., see Ramakrishnan, V. (3,4) 185–193
- Nishiyama, N., see Chung, K. (2) 101–107
- Niu, H.T., C.M. Yang, B. Chen and Q. Dong, Biomarker research and some deduction in superficial bladder cancer cells combined with corresponding stroma (2) 109–116
- Noack, A., see Tsaur, I. (5) 195–204
- Nolen, B.M., C.J. Langmead, S. Choi, A. Lomakin, A. Marrangoni, W.L. Bigbee, J.L. Weissfeld, D.O. Wilson, S. Dacic, J.M. Siegfried and A.E. Lokshin, Serum biomarker profiles as diagnostic tools in lung cancer (1) 3–12
- Nonogaki, S., see Bravo-Calderón, D.M. (1) 51–59
- Nuding, S., see Bartling, B. (3,4) 145–154
- Nunzi, E., see Mearini, L. (3,4) 117–123
- Oliveira, D.T., see Bravo-Calderón, D.M. (1) 51–59
- Ono, M., see Yokomizo, A. (3,4) 175–183
- Oppermann, E., see Tsaur, I. (5) 195–204
- Ormazábal, C., see Folio, C. (1) 35–41
- Ouerhani, S. and A.B.A. Elgaaied, The mutational spectrum of *HRAS*, *KRAS*, *NRAS* and *FGFR3* genes in bladder cancer (6) 259–266
- Paratore, S., G.L. Banna, M. D'Arrigo, S. Saita, R. Iemmolo, L. Lucenti, D. Bellia, H. Lipari, C. Buscarino, R. Cunsolo and S. Cavallaro, CXCR4 and CXCL12 immunoreactivities differentiate primary non-small-cell lung cancer with or without brain metastases (2) 79–89
- Patiño-García, A., see Folio, C. (1) 35–41
- Peña, C., see Blumenschein, Jr., G.R. (6) 287–298
- Pereira, L.H.M., I.N. Adebisi, A. Perez, M. Wiebel, I. Reis, R. Duncan, W.J. Goodwin, J.J. Hu, V.B. Lokeshwar and E.J. Franzmann, Salivary markers and risk factor data: A multivariate modeling approach for head and neck squamous cell carcinoma detection (5) 241–249
- Perez, A., see Pereira, L.H.M. (5) 241–249
- Pesic, M., see Andjelkovic, T. (6) 277–286
- Porena, M., see Mearini, L. (3,4) 117–123
- Qian, N., see Ma, S. (3,4) 155–162
- Ramakrishnan, V., D. Kushwaha, D.C. Koay, H. Reddy, Y. Mao, L. Zhou, K. Ng, P. Zinn, B. Carter and C.C. Chen, Post-transcriptional regulation of O<sup>6</sup>-methylguanine-DNA methyltransferase MGMT in glioblastomas (3,4) 185–193
- Reck, M., see Blumenschein, Jr., G.R. (6) 287–298
- Reddy, H., see Ramakrishnan, V. (3,4) 185–193
- Reis, I., see Pereira, L.H.M. (5) 241–249

- Ren-Heidenreich, L., see Xu, J. (2) 63–69
- Rodriguez-Canales, J., see Rosado, L.A.R. (3,4) 163–173
- Rosado, L.A.R., J. Rodriguez-Canales and B. Zhang, Association of D4-GDI expression with breast cancer progression (3,4) 163–173
- Ruzdijic, S., see Andjelkovic, T. (6) 277–286
- Saber, M.S., see Man-Sun Sy, M.-S. (6) 251–258
- Saed, G.M., see Fletcher, N.M. (6) 267–275
- Saita, S., see Paratore, S. (2) 79–89
- Sakuma, T., see Yokomizo, A. (3,4) 175–183
- Sawhney, H. and C.A. Kumar, Correlation of serum biomarkers (TSA & LSA) and epithelial dysplasia in early diagnosis of oral precancer and oral cancer (1) 43–49
- Scarponi, E., see Mearini, L. (3,4) 117–123
- Schmitt, L., see Tsauro, I. (5) 195–204
- Sebova, K., I. Zmetakova, V. Bella, K. Kajo, I. Stankovicova, V. Kajabova, T. Krivulcik, Z. Lasabova, M. Tomka, S. Galbavy and I. Fridrichova, *RASSF1A* and *CDHI* hypermethylation as potential epimarkers in breast cancer (1) 13–26
- Shen, L., see Ma, S. (3,4) 155–162
- Siegfried, J.M., see Nolen, B.M. (1) 3–12
- Sierrasesúmagu, L., see Folio, C. (1) 35–41
- Silber, R.-E., see Bartling, B. (3,4) 145–154
- Simm, A., see Bartling, B. (3,4) 145–154
- Singh, A.K., see Gill, K. (3,4) 125–134
- Stankovicova, I., see Sebova, K. (1) 13–26
- Stewart, D.J., see Blumenschein, Jr., G.R. (6) 287–298
- Stojic, J., see Andjelkovic, T. (6) 277–286
- Suehiro, S., see Chung, K. (2) 101–107
- Sun, W., see Zheng, Y. (2) 71–77
- Tainsky, M.A., see Fletcher, N.M. (6) 267–275
- Takakura, M., see Yokomizo, A. (3,4) 175–183
- Tang, D., see Topilow, A.A. (1) 27–33
- Tanic, N., see Andjelkovic, T. (6) 277–286
- Toledo, G., see Folio, C. (1) 35–41
- Tomka, M., see Sebova, K. (1) 13–26
- Topilow, A.A., J.M. Davis, J.J. Vernick, D. Tang, S. Corbett, T. Veltman, S.J. Wagner and C. Gilvarg, Confirmation of a potential biomarker for early-stage pancreatic cancer (1) 27–33
- Triantafyllia, V., see Antonacopoulou, A.G. (5) 213–217
- Tsauro, I., A. Noack, A.M. Waaga-Gasser, J. Makarevic, L. Schmitt, M. Kurosch, T. Huesch, C. Wiesner, S. Wedel, G. Bartsch, H. Ackermann, E. Oppermann, M. Lazariotou, M. Gasser, A. Haferkamp and R.A. Blaheta, Chemokines involved in tumor promotion and dissemination in patients with renal cell cancer (5) 195–204
- Vanhooren, V., see Bartling, B. (3,4) 145–154
- Veltman, T., see Topilow, A.A. (1) 27–33
- Vernick, J.J., see Topilow, A.A. (1) 27–33
- Waaga-Gasser, A.M., see Tsauro, I. (5) 195–204
- Wagner, S.J., see Topilow, A.A. (1) 27–33
- Wanibuchi, H., see Chung, K. (2) 101–107
- Wedel, S., see Tsauro, I. (5) 195–204
- Wei, M., see Chung, K. (2) 101–107
- Weissfeld, J.L., see Nolen, B.M. (1) 3–12
- Wiebel, M., see Pereira, L.H.M. (5) 241–249
- Wiesner, C., see Tsauro, I. (5) 195–204
- Wilson, D.O., see Nolen, B.M. (1) 3–12
- Xin, W., see Man-Sun Sy, M.-S. (6) 251–258
- Xu, J., J. He, H. Yang, X. Luo, Z. Liang, J. Chen, Z. Cai, J. Xu and L. Ren-Heidenreich, Somatic mutation analysis of *EGFR*, *KRAS*, *BRAF* and *PIK3CA* in 861 patients with non-small cell lung cancer (2) 63–69
- Xu, J., see Xu, J. (2) 63–69
- Xu, Q., B. Yuan, F. Xue, L. Zhang, J. Li, H. Guo and T. Yue, OPN gene polymorphisms are associated with susceptibility and clinicopathological characteristics of cervical cancer in a Chinese cohort (5) 233–239
- Xue, F., see Xu, Q. (5) 233–239
- Yamada, T., see Yokomizo, A. (3,4) 175–183
- Yamano, S., see Chung, K. (2) 101–107
- Yang, C.M., see Niu, H.T. (2) 109–116
- Yang, H., see Xu, J. (2) 63–69
- Yokomizo, A., M. Takakura, Y. Kanai, T. Sakuma, J. Matsubara, K. Honda, S. Naito, T. Yamada and M. Ono, Use of quantitative shotgun proteomics to identify fibronectin 1 as a potential plasma biomarker for clear cell carcinoma of the kidney (3,4) 175–183
- Yoo, J., see Ha, S.-A. (5) 219–231
- Yuan, B., see Xu, Q. (5) 233–239
- Yuan, X., see Zheng, Y. (2) 71–77
- Yue, T., see Xu, Q. (5) 233–239
- Yun, S.-J., see Jeong, P. (5) 205–211
- Zalacain, M., see Folio, C. (1) 35–41
- Zandueta, C., see Folio, C. (1) 35–41
- Zhang, B., see Rosado, L.A.R. (3,4) 163–173

- Zhang, L., see Xu, Q. (5) 233–239
- Zheng, Y., L. Cui, W. Sun, H. Zhou, X. Yuan, M. Huo, J. Chen, Y. Lou and J. Guo, MicroRNA-21 is a new marker of circulating tumor cells in gastric cancer patients (2) 71–77
- Zhou, H., see Zheng, Y. (2) 71–77
- Zhou, L., see Man-Sun Sy, M.-S. (6) 251–258
- Zhou, L., see Ramakrishnan, V. (3,4) 185–193
- Zinn, P., see Ramakrishnan, V. (3,4) 185–193
- Zmetakova, I., see Sebova, K. (1) 13–26
- Zucchi, A., see Mearini, L. (3,4) 117–123